S1P Deficiency Prolongs Endothelial Barrier Recovery After Fontan Operation

描述（由申请方提供）：本提案的总体目标是通过研究血管内皮屏障功能来解决Fontan手术后发生的广泛临床问题，即持续性胸腔积液。该建议的基本假设是，接受Fontan手术的单心室生理学儿童经历了继发于心肺转流（CPB）的严重炎症效应的血管通透性紊乱。因此，确定恢复血管内皮屏障的治疗靶点可能对改善Fontan手术后的术后护理至关重要。1-磷酸鞘氨醇（S1 P）是一种磷脂，可与内皮细胞上的G蛋白偶联受体相互作用，介导内皮屏障功能的增强，从而降低血管通透性。S1 P在体内调节血管通透性的关键作用已在动物模型中得到说明。例如，缺乏负责S1 P生物合成的两种酶之一鞘氨醇激酶-1的小鼠，响应于脂多糖（LPS）或PAR-1活化诱导的炎性损伤，显示肺微血管通透性增加和水肿形成水平更高。重要的是，在小鼠和犬中静脉内给予S1 P已被证明通过减少肺血管渗漏和肺内分流在急性肺损伤中发挥保护作用。我们对Fontan患者血浆的初步分析显示，HDL的术后血浆水平降低，HDL是促进内皮屏障的鞘脂、鞘氨醇-1-磷酸（S1 P）的主要载体。基于这些发现，我们假设暴露于CPB后儿童血浆HDL-S1 P水平降低，并预测持续性胸腔积液和术后恢复时间较长。此外，我们假设持续性胸腔积液儿童的血液样本将显示破坏屏障的倾向或缺乏促进屏障的能力的证据，这两种情况都可以通过外源性给予S1 P来克服。为了解决这些相互关联的假设，有两个具体的目的：1）确定血浆S1 P水平是否与术后恢复延长的临床标志物（即，持续性胸腔积液），和2）确定由来自Fontan手术患者的血浆样品诱导的屏障完整性水平，并确定这是否与S1 P水平和/或术后胸腔积液的严重性相关。这些后续研究还将确定外源性给予S1 P是否可以增加样本的能力，以将体外屏障增强到使用术前样本达到的水平。该应用的目的可能导致新的基于S1 P的策略，用于治疗Fontan患者和其他接受CPB的婴儿和儿童的血管通透性紊乱。

DESCRIPTION (provided by applicant): The overall goal of this proposal is to address a widespread clinical problem occurring after the Fontan operation, persistent pleural effusions, through the investigation of vascular endothelial barrier function. The foundational hypothesis of this proposal is that children with single ventricle physiology who undergo the Fontan operation experience derangements in vascular permeability secondary to the profound inflammatory effects of cardiopulmonary bypass (CPB). Therefore, identifying therapeutic targets that restore vascular endothelial barrier may be critical to improving post-operative care after the Fontan operation. Sphingosine 1-phosphate (S1P) is a phospholipid that interacts with G protein coupled receptors on endothelial cells and mediates enhancement of endothelial barrier function, thus reducing vascular permeability. The critical role of S1P in regulating vascular permeability in vivo has been illustrated in animal models. For example, mice deficient in one of the two enzymes responsible for S1P biosynthesis, sphingosine kinase-1, display increased pulmonary microvessel permeability and greater levels of edema formation in response to an inflammatory insult induced with lipopolysaccharide (LPS) or PAR-1 activation. Importantly, intravenous administration of S1P in mice and dogs has been shown to play a protective role in acute lung injury by reducing pulmonary vascular leakage and intrapulmonary shunting. Our preliminary analysis of plasma from Fontan patients has revealed a reduction in postoperative plasma levels of HDL, the principle carrier of the endothelial barrier- promoting sphingolipid, sphingosine-1-phosphate (S1P). Based on these findings we hypothesize that plasma HDL-S1P levels are lowered in children after exposure to CPB and are predictive of persistent pleural effusions and longer post-operative recovery time. Additionally, we hypothesize that blood samples from children with persistent pleural effusions will display evidence of either propensity to disrupt barrier or a lack of ability to promote barrier either of which can be overcome by exogenous administration of S1P. To address these inter-related hypotheses there are two specific aims: 1) to determine whether plasma levels of S1P correlate with clinical markers of prolonged postoperative recovery (i.e., persistent pleural effusions) after the Fontan operation, and 2) to determine the level of barrier integrity induced by plasma samples from Fontan operation patients and determine if this correlates with S1P levels and/or severity of post-operative pleural effusions. These later studies will also determine whether exogenous administration of S1P can increase the capacity of the samples to enhance barrier in vitro to levels achieved using preoperative samples. The aims of the application may lead to new S1P based strategies for treatment of derangements in vascular permeability in Fontan patients and other infants and children undergoing CPB.